ResMed | RMD - Cash And Equivalent


ResMed reported $1.42B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Ansell USD 238.3M 674M Jun/2025
Artivion USD 73.43M 19.95M Sep/2025
AtriCure USD 167.43M 19.56M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Cochlear AUD 275.7M 107.4M Jun/2025
Cooper Companies USD 124.9M 13.3M Jun/2025
CSL USD 2.16B 633M Jun/2025
Dexcom USD 917.7M 918M Dec/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Fisher Paykel Healthcare NZD 89.9M 13.3M Jun/2022
Globus Medical USD 526.16M 154.39M Dec/2025
Haemonetics USD 363.37M 66.94M Dec/2025
Hologic USD 2.17B 208.5M Dec/2025
Idexx Laboratories USD 180.07M 28.1M Dec/2025
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 716.1M 41.3M Dec/2025
Integra LifeSciences USD 232.19M 14.27M Sep/2025
Intuitive Surgical USD 9.03B 601.6M Dec/2025
Masimo USD 312.3M 162.7M Sep/2025
Medtronic USD 1.28B 9M Sep/2025
Philips EUR 1.91B 90M Sep/2025
Ramsay Health Care AUD 784.4M 443.3M Jun/2025
ResMed USD 1.42B 33.22M Dec/2025
Sigma Healthcare AUD 16.65M 3.68M Jan/2023
Sonic Healthcare AUD 645M 25.39M Jun/2024
Steris USD 423.7M 104.5M Dec/2025
Teleflex USD 354M 100.3M Sep/2025
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025